Literature DB >> 16552077

Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine.

Catherine A Cosgrove1, Luiz R R Castello-Branco, Tracy Hussell, Amy Sexton, Rafaela Giemza, Richard Phillips, Andrew Williams, George E Griffin, Gordon Dougan, David J M Lewis.   

Abstract

Oral immunization of healthy adults with 10(7) CFU BCG Moreau Rio de Janeiro was well tolerated and significantly boosted gamma interferon responses to purified protein derivative, Ag85, and MPB70 from previous childhood intradermal BCG immunization. Oral BCG offers the possibility of a needle-free tuberculosis vaccine and of boosting the protective immunity from intradermal tuberculosis vaccines.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16552077      PMCID： PMC1418892          DOI： 10.1128/IAI.74.4.2449-2452.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  19 in total

1.  A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination.

Authors:  D F Hoft; E B Kemp; M Marinaro; O Cruz; H Kiyono; J R McGhee; J T Belisle; T W Milligan; J P Miller; R B Belshe
Journal:  J Lab Clin Med       Date:  1999-09

Review 2.  Propelling novel vaccines directed against tuberculosis through the regulatory process.

Authors:  M J Brennan; F M Collins; S L Morris
Journal:  Tuber Lung Dis       Date:  1999

3.  Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren.

Authors:  I Dourado; M H Rios; S M M Pereira; S S Cunha; M Y Ichihara; J C L Goes; L C Rodrigues; A L Bierrenbach; M L Barreto
Journal:  Int J Tuberc Lung Dis       Date:  2003-04       Impact factor: 2.373

4.  Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells.

Authors:  A Lalvani; A A Pathan; H Durkan; K A Wilkinson; A Whelan; J J Deeks; W H Reece; M Latif; G Pasvol; A V Hill
Journal:  Lancet       Date:  2001-06-23       Impact factor: 79.321

5.  Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence.

Authors:  M M Tala-Heikkilä; J E Tuominen; E O Tala
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

6.  BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics.

Authors:  A Lotte; O Wasz-Höckert; N Poisson; N Dumitrescu; M Verron; E Couvet
Journal:  Adv Tuberc Res       Date:  1984

7.  Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.

Authors:  C C Leung; C M Tam; S L Chan; M Chan-Yeung; C K Chan; K C Chang
Journal:  Int J Tuberc Lung Dis       Date:  2001-08       Impact factor: 2.373

8.  A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements.

Authors:  L Wang; M O Turner; R K Elwood; M Schulzer; J M FitzGerald
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

Review 9.  The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis.

Authors:  H G Wiker; M Harboe
Journal:  Microbiol Rev       Date:  1992-12

10.  Treatment of disseminated malignant melanoma with high-dose oral BCG.

Authors:  A D Varella; D C Bandiera; A R de Amorim; L A Calvis; I O Santos; N Escaleira; F Gentil
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860
View more
  12 in total

Review 1.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

Review 2.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

3.  Concurrent neurocysticercosis and pulmonary tuberculosis.

Authors:  Chad M Miller; Paul M Vespa
Journal:  Neurocrit Care       Date:  2008-09-23       Impact factor: 3.210

4.  Assessment of Mycobacterium tuberculosis OmpATb as a novel antigen for the diagnosis of bovine tuberculosis.

Authors:  Irene Schiller; H Martin Vordermeier; W Ray Waters; Mitchell Palmer; Tyler Thacker; Adam Whelan; Roland Hardegger; Beatrice Marg-Haufe; Alex Raeber; Bruno Oesch
Journal:  Clin Vaccine Immunol       Date:  2009-07-08

Review 5.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

6.  An investigation of clinical and immunological events following repeated aerodigestive tract challenge infections with live Mycobacterium bovis Bacille Calmette Guérin.

Authors:  Fernanda Schreiber; Zhiming Huo; Rafaela Giemza; Maria Woodrow; Nicola Fenner; Zoe Stephens; Gordon Dougan; Steven Prideaux; Luiz R R Castello-Branco; David J M Lewis
Journal:  Vaccine       Date:  2010-06-15       Impact factor: 3.641

7.  A Single Dose of Oral BCG Moreau Fails to Boost Systemic IFN-γ Responses to Tuberculin in Children in the Rural Tropics: Evidence for a Barrier to Mucosal Immunization.

Authors:  Maritza Vaca; Ana-Lucia Moncayo; Catherine A Cosgrove; Martha E Chico; Luiz R Castello-Branco; David J Lewis; Philip J Cooper
Journal:  J Trop Med       Date:  2012-01-11

8.  Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?

Authors:  Renata Monteiro-Maia; Rosa Teixeira de Pinho
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-09       Impact factor: 2.743

9.  In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals.

Authors:  Imran Saleem; Allan G A Coombes; Mark A Chambers
Journal:  Pharmaceutics       Date:  2019-06-10       Impact factor: 6.321

10.  Oral vaccination with lipid-formulated BCG induces a long-lived, multifunctional CD4(+) T cell memory immune response.

Authors:  Lindsay R Ancelet; Frank E Aldwell; Fenella J Rich; Joanna R Kirman
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.